Compare CVS Health Corp (CVS) vs Chevron Corp (CVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Chevron Corp — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.29B), while Chevron Corp trades at $209.93 (market cap $414.98B). The key difference: Chevron Corp is far larger — about 3.7× CVS Health Corp's market cap, and Chevron Corp pays the higher dividend (3.37%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Chevron Corp for 101 Days on average.
| CVS | CVX | |
|---|---|---|
Market Cap | $112.29B | $414.98B |
Volume | 7,763,676 | 7,575,112 |
Sector | Health | Energy |
52-Week High | $110.60 | $217.73 |
52-Week Low | $70.08 | $146.72 |
Typical Hold Time | 83 Days | 101 Days |
Enterprise Value | $174.64B | $443.52B |
Dividend Yield | 3.03% | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
CVX trades at $211.605, up 1.92% today, with a neutral technical signal. The stock shows strong earnings beats in recent quarters, with Q2 2026 EPS of $6.06 exceeding the $5.55 estimate. Revenue for 2025 was $184.43B, though net income declined to $12.30B. Analyst consensus is bullish with a $208.31 price target and 62% buy ratings. Recent news highlights Chevron's $13.8B investment in Argentina's Vaca Muerta and geopolitical impacts on oil prices.
The outlook for CVX is supported by high oil prices and strategic investments, but risks include volatile energy markets and declining profit margins. Earnings growth and dividend stability remain key catalysts, though geopolitical tensions and operational execution pose challenges for sustained shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →
